NCT04815213

The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans

The Use of Expanded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans: Phase I Clinical Trial

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Jordan · Academic / Other
• Sex: Female
• Age: 18 Years – 38 Years
• Healthy volunteers: Not accepted

Summary

Autologous bone marrow-derived mesenchymal cells will be injected into patients diagnosed with premature ovarian failure

Detailed description

MSCs in passage-2 culture will be washed with PBS and detached with trypsin/EDTA (0.25%). After that, the cells will be suspended at a density of 20×106 cells/ 2 ml normal saline and loaded into 3 ml sterile syringes. The cells should be infused within 2 hours of release. Tests and follow up are to be monthly.

Conditions

• Premature Ovarian Failure

Interventions

Type	Name	Description
BIOLOGICAL	expanded autologous bone marrow derived MSC Intravaginally	Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
BIOLOGICAL	expanded autologous bone marrow derived MSC Laporoscopic	Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
BIOLOGICAL	EV	Extracellular vesicles injection

Timeline

• Start date: 2022-01-01
• Primary completion: 2025-01-31
• Completion: 2027-01-31
• First posted: 2021-03-24
• Last updated: 2025-01-28

Locations

1 site across 1 country: Jordan